LivaNova PLC
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.01B | $964.9M | $291.6M | $282.2M | $255.4M | $218.7M | $192.4M | $163.7M |
| Neuromodulation | — | — | — | $282.2M | $255.4M | $218.7M | $192.4M | $163.7M |
| Cardiovascular | — | — | — | $0 | $0 | $0 | $0 | $0 |
| CRM | — | — | — | $0 | $0 | $0 | $0 | $0 |
| Other | — | — | — | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | $353.2M | $367.8M | $27.3M | $27.4M | $21.9M | — | — | — |
| Gross Profit | $651.6M | $559.5M | $264.2M | $254.7M | $232.4M | — | — | — |
| Gross Margin | 64.4% | 58.0% | 90.6% | 90.2% | 91.0% | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $109.5M | $82.1M | $42.2M | $45.2M | $41.6M | — | — | — |
| SG&A Expense | $380.1M | $355.2M | $123.6M | $120.6M | $112.5M | — | — | — |
| Operating Income | $96.5M | $33.4M | $88.7M | $80.0M | $78.3M | — | — | — |
| Operating Margin | 9.5% | 3.5% | 30.4% | 28.4% | 30.7% | — | — | — |
| Interest Expense | $7.8M | $10.6M | $21.0K | $20.0K | $119.0K | — | — | — |
| Pretax Income | $121.1M | $25.7M | $89.3M | $79.9M | $75.3M | — | — | — |
| Income Tax Expense | $50.0M | $5.1M | $31.4M | $25.0M | $28.9M | — | — | — |
| Net Income | $-25.1M | $-62.8M | $57.8M | $54.9M | $46.4M | — | — | — |
| Net Margin | -2.5% | -6.5% | 19.8% | 19.5% | 18.2% | — | — | — |
| EPS (Basic) | $-0.52 | $-1.29 | $2.19 | $2.02 | $1.68 | — | — | — |
| EPS (Diluted) | $-0.52 | $-1.28 | $2.17 | $2.00 | $1.66 | — | — | — |
| Shares Outstanding (Basic) | 48.2M | 48.9M | 26.4M | 27.1M | 27.6M | — | — | — |
| Shares Outstanding (Diluted) | 48.5M | 49.0M | 26.6M | 27.5M | 28.0M | — | — | — |
| Dividends Per Share | — | — | — | — | — | — | — | — |